AI-Based Digital Pathology Shows that Denifanstat Improves Multiple Parameters of Fibrosis and Reduces Progression to Cirrhosis in MASH patients with F2/F3
AASLD The Liver Meeting
NASH
Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity
8th Annual MASH Drug Development Summit
Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model
7th Obesity and NASH Drug Development Summit
